Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation

Trial Profile

Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Lisdexamfetamine (Primary) ; Fluoxetine
  • Indications Mood disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Nov 2016 Status changed from recruiting to completed.
    • 11 Jan 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
    • 11 Jan 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top